Teniposide (Teniposidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antitumor agents of vegetable origin

Included in the formulation
АТХ:

L.01.C.B.02   Teniposide

Pharmacodynamics:

Inhibits topoisomerase II, due to which it breaks the synthesis of nucleic acids, due to high lipophilicity rapidly penetrates through cell membranes. It is embedded in DNA, breaking their synthesis, interrupting the chain of electron transport in the mitochondria, interrupting the respiration of tumor cells.

Pharmacokinetics:

After intravenous administration, the plasma protein is more than 99% bound. Penetrates through the blood-brain and placental barrier. Metabolism in the liver.

The elimination half-life is 9.8 hours. Elimination by the kidneys, up to 12% in unchanged form.

Indications:

It is used for the treatment of acute leukemia, non-small cell lung cancer, neuroblastoma, bladder cancer, malignant brain tumors. Used for lymphoma, resistant to the action of anthracyclines.

ICD-10

II.C30-C39.C34   Malignant neoplasm of bronchi and lungs

II.C64-C68.C67   Malignant neoplasm of bladder

II.C69-C72.C71   Malignant neoplasm of brain

II.C81-C96.C81   Hodgkin's disease [lymphogranulomatosis]

II.C81-C96.C83   Diffuse non-Hodgkin's lymphoma

II.C81-C96.C85.7   Other specified types of non-Hodgkin's lymphoma

II.C81-C96.C95   Leukemia of unspecified cell type

Contraindications:

Hepatic and renal failure, expressed myelosuppression, individual intolerance, children under 12 months.

Carefully:

Thrombocytopenia, leukopenia, hypoalbuminemia, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Use in children

Intravenously slow, 130-180 mg / m2 body surface 1 time per week for 4 weeks or 1-15 mg / kg every 2 weeks.

The highest dose for 1 week: 180 mg / m2 surface of the body.

The highest single dose: 180 mg / m2 surface of the body.

Adults

Intravenously slow, 40-80 mg / m2 body surface for 5 days with a break of 2-3 weeks. At a brain tumor - on 100-130 mg / m2.

The highest daily dose: 130 mg / m2 surface of the body.

The highest single dose: 130 mg / m2 surface of the body.

Side effects:

Central and peripheral nervous system: fatigue, dizziness, aphasia, convulsions.

Hemopoietic system: anemia, thrombocytopenia, and leukopenia.

Respiratory system: cough, rapid breathing, interstitial pneumonitis.

The cardiovascular system: phlebitis, thrombophlebitis, tachycardia, bradycardia, atrioventricular blockade, cardiomyopathy, myocarditis, pericarditis.

Digestive system: ulcerative stomatitis, anorexia, nausea, rarely - melena, diarrhea, pancreatitis, fatty degeneration of the liver.

Musculoskeletal system: arthralgia, myalgia.

urinary system: nephropathy, cystitis.

Reproductive system: oligospermia, decreased libido, menstrual irregularities, impotence.

Dermatological reactions: alopecia, itching.

Allergic reactions.

Overdose:

Myelosuppression.

Treatment is symptomatic, blood transfusion, transplantation of red bone marrow.

Interaction:

Increase the clearance of teniposide phenobarbital, phenytoin and ciclosporin.

Special instructions:

Treatment with teniposide is carried out under the supervision of a doctor who has experience of antitumor therapy. Monitoring of liver and kidney functions, blood tests.

In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

Instructions
Up